[This is the second part of a two-part series on electronic media resources. Last month we discussed the California STD/HIV Prevention Training Center's Youth Social Marketing Toolkit.]
With drug manufacturers retreating in recent years from voluntary discounts to family planning and other public clinics, providers increasingly rely on federally mandated discounts.
Several descriptive phrases are now being coined when family planning providers discuss such highly effective reversible methods as intrauterine contraception (ParaGard Copper T 380A intrauterine device, Duramed Pharmaceuticals, and the Mirena levonorgestrel intrauterine system, Bayer HealthCare Pharmaceuticals) and the contraceptive implant (Implanon, Schering-Plough Corp.).
An analysis presented at the 2010 National STD Prevention Conference gives a chilling look at impact of HIV and syphilis among U.S. gay and bisexual men.
An approach designed to reduce HIV and sexually transmitted diseases (STDs) in adolescents previously used exclusively by academic researchers now has been shown to be successfully implemented by community-based organizations (CBOs).
Being overweight or obese increases the risk of cirrhosis. In this study, excess body weight contributed to almost 20% of the cirrhosis-related hospital admissions and deaths, while alcohol contributed to almost 50%.
Contrary to the current guidelines, in the long term, an average of approximately 60 min/day of moderate-intensity activity for women is required to be successful in maintaining a normal weight.
The FDA has approved a miconazole buccal tablet for the treatment of oropharyngeal candidiasis. This once-daily mucoadhesive buccal tablet provides slow release of the drug over the course of the day. The tablet is marketed by Strativa Pharmaceuticals as Oravig™.
